Pfizer Inc. (PFE)
High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Pfizer's financial health is concerning, with unsustainable dividend payout ratios and negative debt-to-equity ratios, but future projections suggest a potential recovery. Despite political risks and activist investor concerns, PFE's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment.
Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?
Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ET Company Participants Dave Denton - CFO Andrew Baum - Chief Strategy and Innovation Officer, EVP Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good to start. All right.
Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY revenue growth, driven by products like Paxlovid and Comirnaty. Despite high valuation multiples, a DCF analysis suggests Pfizer's intrinsic value is $37.56 with 3% growth, indicating potential undervaluation.
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.
Pfizer names Chris Boshoff as new R&D chief, WSJ reports
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday.
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer's cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
